Is Cardiometabolic Ripe For A Revival?
Exploring Trends In The Cardiometabolic Field
Executive Summary
Opportunities in the cardiometabolic field are increasing, following a period of limited investment from larger biopharma players. Still, challenges remain, such as accessing funding at the earlier stages of development.
You may also be interested in...
2020 VC Landscape: Reviewing The First Six Months
A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June.
Alzheimer’s Is Not A Silent Disease If You Are Listening
Experts discuss the future of brain health, changing the stereotypical view of an Alzheimer’s patient and how technology and science have evolved the treatment possibilities for dementia patients in 2020 – even if ‘clinical practice is taking a long time to catch up.’
NASH Backlash: Intercept Delay Raises Questions
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
Need a specific report? 1000+ reports available
Buy Reports